Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.45 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.45 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.45 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.45 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.45 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10285807 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AHTR2CMEN1 | |
| SCHEMBL5787375 | 0.90 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9AHTR2CMEN1 | |
| SCHEMBL1870162 | 0.90 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9AHTR2CMEN1 | |
| SCHEMBL14372548 | 0.89 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9AHTR2CMEN1 | |
| SCHEMBL16525824 | 0.88 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9AHTR2CMEN1 | |
| SCHEMBL603957 | 0.87 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AHTR2CMEN1 | |
| SCHEMBL23186133 | 0.85 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AHTR2CMEN1 | |
| SCHEMBL13330343 | 0.85 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AHTR2CMEN1 | |
| SCHEMBL1439624 | 0.85 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AHTR2CMEN1 | |
| SCHEMBL2379232 | 0.85 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AHTR2CMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8829193-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-09 | — | — | US | disclosed |
| US-20120202851-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202851-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | SMN1; SMN2 3818/4885NPC1 1582/4885RAB9A 3326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.